Abstract 3914: BTK and MALT1 are critical for cell adhesion and dissemination in mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3914
Abstract: Bruton’s tyrosine kinase (BTK) is a great target in mantle cell lymphoma (MCL). This is evident by multiple FDA approvals of covalent BTK inhibitors (BTKi, e.g. ibrutinib, acalabrutinib and zanubrutinib) and recent exciting clinical data… read more here.
Keywords: cell; malt1; growth; btki ... See more keywords
Abstract CT147: Phase I clinical study of Bruton’s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct147
Abstract: Purpose: This clinical study is to evaluate HBW-3220, a novel reversible BTK inhibitor (BTKi) with an improved in vitro profile than the existing non-covalent drugs pirtobrutinib (LOXO-305, approved) and MK-1026 (Phase III). HBW-3220 shows superior… read more here.
Keywords: hbw 3220; cell; lymphoma; study ... See more keywords
Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198724
Abstract: Introduction: Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment (tx) landscape of CLL/SLL. However, BTKi are associated with an increased risk of bleeding events that may complicate their use in patients (pts) with thrombotic… read more here.
Keywords: first bleed; real world; cll sll; btki ... See more keywords
Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-205119
Abstract: Background: The first-in-class Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is associated with an increased risk of atrial fibrillation (AF), ventricular arrhythmia, and sudden death. While next-generation BTKis, acalabrutinib and zanubrutinib, are more selective, growing evidence… read more here.
Keywords: clinically significant; risk; significant arrhythmia; arrhythmia ... See more keywords
Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2869
Abstract: Background: In recent decades, standard upfront therapy for mantle cell lymphoma (MCL) has featured chemoimmunotherapy (CIT) regimens of varying intensity followed by autologous transplant in eligible patients. Outcomes with CIT suggest that this strategy can… read more here.
Keywords: btki; mantle cell; cell; upfront therapy ... See more keywords
Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7934
Abstract: Background: Given the introduction of 2nd generation safer and more tolerable BTKis to treat first- line Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) patients, Integra Connect evaluated the use of these therapies among patients at… read more here.
Keywords: treatment; 2nd generation; first line; line ... See more keywords
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2023023525
Abstract: Patients with mantle cell lymphoma (MCL) who experience first relapse/refractoriness can be categorized into early or late progression-of-disease (POD) groups, with a threshold of 24 months from the initial MCL diagnosis. Bruton tyrosine kinase inhibitors… read more here.
Keywords: late pod; pod; patients mantle; mantle cell ... See more keywords
Risk of new-onset hypertension in patients (pts) with newly diagnosed chronic lymphocytic leukemia (CLL) treated with Bruton tyrosine kinase inhibitors (BTKi): A real-world data study using the Symphony Health Solution database.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e19014
Abstract: e19014 Background: BTKis provide an important therapeutic option for pts diagnosed with CLL. Concerns have arisen about a potential association with the risk of cardiovascular events with BTKi. Using the Symphony Health Solutions database, this… read more here.
Keywords: new onset; onset hypertension; cll; risk new ... See more keywords
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e19048
Abstract: e19048 Background: This study aimed to examine treatment adherence and healthcare resource utilization (HCRU) of BTKi treatment in mantle cell lymphoma (MCL). Methods: The Symphony Integrated Dataverse (IDV) was used to conduct a retrospective observational… read more here.
Keywords: treatment; adherence healthcare; adherence; ibrutinib zanubrutinib ... See more keywords
Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e23271
Abstract: e23271 Background: BTKis are the standard of care for CLL/SLL in the first-line (1L) and relapsed/refractory (R/R) settings. The next-generation BTKi zanubrutinib (zanu) demonstrated superiority over the first-generation BTKi ibrutinib (ibr) in treating R/R CLL,… read more here.
Keywords: zanu; oncology; cll sll; btki ... See more keywords
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies
Sign Up to like & getrecommendations! Published in 2024 at "Cancers"
DOI: 10.3390/cancers16203434
Abstract: Simple Summary Bruton’s tyrosine kinase inhibitors (BTKi) have revolutionized the treatment of various B-cell lymphoid malignancies. However, acquisition of resistance to BTKi has emerged as an important clinical challenge. Herein, we provide a detailed review,… read more here.
Keywords: resistance; cell lymphoid; btk; lymphoid malignancies ... See more keywords